MedTrace Logo

Dupilumab De-escalation in Pediatric Atopic Dermatitis

NCT06116526 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-20

No results posted yet for this study

Summary

This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.

Conditions

Interventions

DRUG

Dupilumab - Discontinuation

Drug injections are discontinued.

DRUG

Dupilumab - Dose Reduction

The drug is given as a subcutaneous injection.

DRUG

Dupilumab - Standard Dose

The drug is given as a subcutaneous injection.

Sponsors & Collaborators

Principal Investigators

  • Joy Wan, MD MSCE · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2027-04-01
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06116526 on ClinicalTrials.gov